Despite nearly a century of research showing bacteriocins can kill dangerous bacteria while sparing beneficial ones, none has been approved for human therapeutic use — and this review explains why.
0 approved for human useDespite nearly 100 years of bacteriocin research and proven antimicrobial activity, no bacteriocin has been approved as a human therapeutic
What the researchers found
Bacteriocins are a diverse class of antimicrobial peptides produced by bacteria that show strong potential as alternatives to conventional antibiotics. Despite nearly a century of research, no bacteriocin has been approved for therapeutic use in humans — they remain limited to food preservation applications like nisin.
The review catalogs the broad structural diversity of bacteriocins, from simple linear peptides to extensively post-translationally modified structures. Their mechanisms of action include membrane disruption, pore formation, and inhibition of cell wall synthesis. Crucially, many bacteriocins have narrow-spectrum activity, meaning they can target specific pathogens while leaving beneficial gut bacteria intact — a major advantage over broad-spectrum antibiotics.
Modern tools including metagenomic mining and bioengineering are accelerating the discovery and optimization of novel bacteriocins, but translation from lab to clinic has been stalled by challenges in formulation, stability, and regulatory pathways.
Why it matters
With antimicrobial resistance declared a global health crisis, the world urgently needs new classes of antimicrobials. Bacteriocins offer a promising but underexploited avenue — they're naturally produced, can be engineered for specificity, and could potentially spare the microbiome. This review from a top-tier journal maps out exactly where the field stands and why these peptides haven't yet reached the clinic.
The numbers in context
Nearly 100 years of bacteriocin research · 0 bacteriocins currently approved for human therapeutic use · Narrow and broad spectrum activity documented · Published in Nature Reviews Microbiology (IF ~69)
How the study worked
Narrative review published in Nature Reviews Microbiology. The authors surveyed the literature on bacteriocin diversity, structure, mechanisms of action, resistance mechanisms, discovery methods (including metagenomic mining), bioengineering strategies, and barriers to clinical translation.
Who was studied
Not applicable (review article)
What this study cannot tell us
As a narrative review, this paper synthesizes existing knowledge rather than presenting new experimental data. The authors note that most bacteriocins remain incompletely characterized, and the review cannot fully address why clinical translation has been so slow beyond identifying general barriers.
How to read the evidence
This is a comprehensive review published in Nature Reviews Microbiology, one of the highest-impact journals in the field. While it does not present new experimental data, it synthesizes decades of research from a highly authoritative perspective.
When this study was published
Published in 2024 in Nature Reviews Microbiology. This is a current, state-of-the-art review reflecting the latest understanding of bacteriocin science and clinical translation barriers.
The bigger picture
The antimicrobial resistance crisis is one of the biggest threats to global health, with drug-resistant infections killing over a million people annually. Bacteriocins represent a largely untapped reservoir of antimicrobial peptides that could complement or replace failing antibiotics. This review is a comprehensive roadmap of the field's progress and remaining obstacles, making it essential reading for understanding where peptide-based antimicrobials are headed.
Questions still open
- What specific regulatory or formulation changes would be needed to bring the first bacteriocin to human clinical use?
- Can metagenomic mining and AI-driven design accelerate bacteriocin discovery enough to address the resistance crisis?
- Would engineered narrow-spectrum bacteriocins be viable as microbiome-sparing alternatives to broad-spectrum antibiotics?
Common questions
What are bacteriocins and how do they differ from antibiotics?
If bacteriocins are so promising, why aren't they used as medicines?
Read the original research
Bacteriocin diversity, function, discovery and application as antimicrobials.
Nature reviews. Microbiology, 22(9), 556-571
Citation
Sugrue, Ivan; Ross, R Paul; Hill, Colin. (2024). Bacteriocin diversity, function, discovery and application as antimicrobials.. Nature reviews. Microbiology, 22(9), 556-571. https://doi.org/10.1038/s41579-024-01045-x